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The transcription factor Pax2 is essential for the development of the urogenital system. Pax2 expression can be detected by mouse
embryonic day 8.5 (E8.5) in the region of intermediate mesoderm fated to become the nephric duct, pronephros, and mesonephros. Elements
that direct Pax2 expression to nephrogenic precursor cells must be responding to positional information that controls nephrogenic fate. A 4.1-
kb Pax2 promoter/enhancer fragment directs expression of a lacZ reporter to the nephrogenic region and the midbrain–hindbrain junction in
transgenic mice. As kidney development proceeds, transgene expression is limited to the nephric duct and its derivatives, but not the
metanephric mesenchyme. The early expression driven by the 4.1 promoter does not require the Pax2 protein, demonstrating that it receives
positional information in the absence of a developing pro- or mesonephros. We have identified two DNAseI hypersensitive regions within
this promoter, one at the start site of transcription initiation and a second approximately 2-kb upstream. Deletion of the more distal site
significantly attenuates lacZ expression in the nephrogenic region but not in the midbrain–hindbrain region. DNA footprinting of this
fragment revealed a highly conserved sequence between mouse and human Pax2 promoter sequences. Using fractionated nuclear extracts, we
identified the transcription factor Yin Yang 1 (YY1) as the protein that binds to this conserved sequence. Deletion of the YY1 element
significantly attenuated expression of a full-length 4.1 promoter. Moreover, inclusion of this YY1 binding element significantly enhanced
expression of a minimal Pax2 promoter/enhancer transgene in E12 embryos. These data point to a novel role for YY1 in the establishment of
high level tissue-specific expression within the intermediate mesoderm.
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broad spectrum of phenotypes, including optic nerve colo-Introduction
During the process of embryonic development, many
genes essential for growth, differentiation, and tissue spec-
ification are expressed in complex spatial and temporal
patterns, often regulated by multiple enhancer and promoter
elements (Levine and Tjian, 2003). For example, in all
vertebrates, the Pax2 gene is one of the earliest markers
for formation of the midbrain–hindbrain junction (Nornes et
al., 1990; Pfeffer et al., 1998). Yet, Pax2 expression is also
prominent in the optic cup, the otic vesicle, and the
intermediate mesoderm and its derivatives, the urogenital
system (Dressler and Douglass, 1992). In each of these
tissues, Pax2 is essential as mutations are associated with a0012-1606/$ - see front matter D 2003 Elsevier Inc. All rights reserved.
doi:10.1016/j.ydbio.2003.11.002
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agenesis (Eccles and Schimmenti, 1999).
The role of Pax2 and the related gene Pax8 have been
well characterized in the developing kidney. The kidney
derives from the intermediate mesoderm, located between
the paraxial and the lateral plate mesoderm (Dressler, 2002).
Pax2 and Pax8 expressions mark this region at the 4–6
somite stage (Bouchard et al., 2002). By the 12 somite
stage, an epithelial tube, the nephric duct, is formed in the
intermediate mesoderm and extends caudally towards the
cloaca. In Pax2/8 double mutant embryos, there is no
evidence of nephric duct formation (Bouchard et al.,
2002). Pax2 is also expressed in mesoderm surrounding
the nephric duct, which form the mesonephric tubules and
the metanephric, or adult, kidney. In Pax2 null embryos, the
nephric duct is formed most likely as a result of the
redundant function of Pax8. However, the mesonephric
and metanephric regions are unable to form epithelia (Bro-
phy et al., 2001; Torres et al., 1995). Thus, Pax2/8 are
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renal epithelia derived from the intermediate mesoderm.
Gain of function experiments suggest that Pax2 is sufficient
to specify the intermediate mesoderm as a renal progenitor
region (Bouchard et al., 2002).
The neural and mesodermal components of Pax2 expres-
sion are controlled by distinct tissue-specific enhancers
(Kuschert et al., 2001; Pfeffer et al., 2002; Rowitch et al.,
1999). These two enhancers, termed midbrain–hindbrain
and kidney specific, are located approximately 3- to 4-kb
upstream of the transcription start site. These enhancers can
recapitulate some aspects of the Pax2 expression pattern in
transgenic mice. The Pax2 kidney-specific enhancer is
active early in the intermediate mesoderm, similar to the
endogenous gene (Kuschert et al., 2001). Expression of
reporter genes then becomes restricted to the nephric duct
epithelia and to the ureteric bud, a posterior outgrowth of the
nephric duct. This minimal Pax2 enhancer neither drives
expression in the metanephric mesenchyme, which normally
expresses Pax2, nor drives expression to the same levels of
protein as the full-length promoter. The early kidney-spe-
cific enhancer does contain cis-acting elements that generate
the intermediate mesoderm-specific expression and most
likely responds to extracellular positional cues, though the
nature of such signals is poorly defined. However, the
kidney-specific enhancer is not sufficient for high level
expression and must work in concert with other elements
of the full-length promoter to establish the critical levels of
Pax2 needed for renal development.
To identify other cis-acting elements that control Pax2
expression in the intermediate mesoderm, DNAseI hyper-
sensitive sites were mapped in the Pax2 promoter–enhancer
region. A highly conserved DNAseI hypersensitive site was
found between the minimal enhancer and the Pax2 transcrip-
tion start site. Upon deletion of this sequence, the activity of
the minimal enhancer was greatly reduced in transgenic
mice. Using fractionated nuclear extracts, we identified the
transcription factor Yin Yang 1 (YY1) as the protein that
bound to this conserved sequence. The YY1 gene is widely
expressed and is thought to both positively and negatively
regulate transcription. These data point to a novel role for
YY1 in the establishment of high level tissue-specific
expression within the intermediate mesoderm of the mouse.Materials and methods
DNA constructs and oligonucleotide primers
The p4.1lacZ plasmid contains 4167-bp upstream of the
Escherichia coli b-galactosidase coding region. The
p4.1Dlacz vector has a 334-base pair deletion from n1392
to n1725 of the full-length 4.1-kb Pax2 BamHI fragment. For
pApa0.4 EGFP, an NcoI digest of the pPax2.Apa1(0.4).lacZ
(gift from Andreas Kispert) was cloned into a SalI/SmaI
digested pEGFP-1. pYY1 Apa0.4 EGFP was constructed byinserting an annealed oligo with top strand sequence 5V-
CAACCCGGGAGCGCCATCTACAC-3Vwith 5V-GATC-3V
free ends into the BglII site of pApa0.4 EGFP. pApa0.4
YY1 EGFP was constructed by inserting the annealed oligo
listed previously, except with 5V-GTAC-3Vfree ends into the
Asp718 site of pApa0.4 EGFP. p4.1DYY1 EGFP was con-
structed by deleting an 11 base pair sequence spanning the
Yin Yang 1 site by using a Site Directed Mutagenesis Kit
(Stratagene Corp, La Jolla, CA), according to the manufac-
turer’s protocol using the top primer sequence of 5V-
TTGGCCAAAGCAAACCCGGGAGGGCCTTGAGAG-
GAAGGCATTG-3V. The cosmid cos26lacz was generated by
inserting the lacZ coding region into a unique NotI site in the
5VUTR of exon 1. p9.0lacZ contains a 9-kb HindIII–NotI
fragment cloned upstream of lacZ. p4.1GL3 was constructed
by cloning the 4.1-kb Pax2 promoter fragment listed above
into the BglII/HindIII sites of pGL3 (Promega, Madison,
WI.). Similarly, p4.1D GL3 was constructed by cloning the
4.1D fragment listed above into the BglII/HindIII sites of
pGL3. The sequence of all constructs was verified by
sequencing the DNA constructs. pCMV-h-gal, described
previously (Brophy et al., 2001), was used to normalize for
transfection efficiency. pCMV-YY1 was a kind gift from D.
Markowitz, and contains a full-length cDNA for YY1 as an
EcoRI fragment in the pCB6+ vector (Park and Atchison,
1991).
Transgenic mice
Purified DNA was microinjected into fertilized eggs
obtained by mating (C57BL/6 X SJL)F1 or C57BL/6 female
micewithmating (C57BL/6X SJL) F1malemice. Linearized
DNAwas injected into pronuclei as described (Hogan et al.,
1994) by the Transgenic Core at the University of Michigan.






b-Galactosidase staining and GFP visualization
For h-galactosidase staining, embryos were fixed for 30
min at 4jC in phosphate-buffered saline (PBS) containing
1% formaldehyde, 0.2% gluteraldehye, and 0.02% NP40
(Sigma, St. Louis, MO), washed twice in PBS at 4jC for 20
min, and stained overnight in PBS containing 5 mM
K3Fe(CN) 6, 5 mM K4Fe(CN) 6, 2 mM MgCl2, and 1 mg/
ml X-gal (Sigma). For GFP detection, embryos were fixed
in 4% paraformaldehyde in PBS for 30 min at 4jC and
washed three times in PBS. GFP expression was visualized
by a Leica MZIII FL fluorescence microscope and photo-
graphed with a SONY DKC 5000 video camera. The film
speed was set at 800, and exposure time was 4 s for all
embryos.
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Nuclei from E17 mouse kidneys and livers, 293 cells,
and 3T3 cells were isolated by sucrose step gradients as
described (Phelps and Dressler, 1996). The nuclei were
resuspended in Elution Buffer, 25 mM HEPES, pH 7.8,
420 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM
DTT, 25% glycerol and protease inhibitors, and dounced 10
times with a tight fitting Type B homogenizer. The samples
were rotated for 30 min at 4jC and centrifuged at 14000 
g for 20 min at 4jC. The supernatant was dialyzed against
Z-buffer, 25 mM HEPES, pH 7.8, 100 mM KCl, 12.5 mM
MgCl2, 1 mM DTT, 0.1% NP40, 20% glycerol. Samples
were aliquoted, frozen on dry ice, and stored at 80jC.
For mapping DNAseI hypersensitive sites, nuclei were
resuspended in PBS with 10 mM MgCl2 and aliquoted into
equal amounts on ice. After addition of increasing concen-
trations of RNAse-free DNAseI (Roche Inc.), samples were
digested for 10 min on ice then terminated by addition of
three volumes DNA extraction buffer (10 mM Tris, pH 8,
100 mM NaCl, 1% SDS, 5 mM EDTA). Protease-K was
added to 0.5 mg/ml and samples digested overnight. After
extraction with phenol/chloroform (1:1) and ethanol precip-
itation, 5 Ag of DNAwas cut with HindIII or BamHI, run on
0.7% agarose gels, and Southern blotted to Genescreen
nylon membranes (NEN). The probes corresponding to the
3Vend of the BamHI and HindIII fragments were labeled by
random priming.
DNAseI footprinting and EMSA analysis
Plasmid DNAs were digested with restriction enzymes
and individual fragments were isolated on low melting point
agarose. The fragments were labeled with 32-P-dCTP and
32-P-dGTP by the Klenow fill-in reaction. The incubation
with nuclear extracts and DNAse digestions were as de-
scribed (Brophy et al., 2001). The A + G chemical cleavage
reactions were performed with piperidine as described
(Maxam and Gilbert, 1980).
For EMSA analysis, nuclear protein extracts were incu-
bated in 10 Al of buffer (12.5 mM HEPES pH 7.8, 50 mM
KCL, 0.5 mM DTT, 6.25 mM MgCl2, 10% glycerol) with 1
Ag poly dIdC and 10000 cpm of end-labeled oligonucleotide
for 30 min at room temperature. For competition experi-
ments, unlabelled DNA was added to the binding reactions.
Recombinant hexahistidine tagged Yin Yang 1 (TA-150-1,
Austral Biologicals, San Ramon, CA) was incubated in the
buffer listed above, with added 0.1 mM ZnSO4. For antibody
supershifting, 0.1 Ag of anti-YY1 (SC-7341X, Santa Cruz)
or anti-Ku86 (SC-9034, Santa Cruz) was added after 15 min.
The DNA–protein complexes were resolved on either 4% or
6% non-denaturing polyacrylamide gels in Tris–Borate–
EDTA buffer at 120 V for 2 or 3 h. Gels were dried and
exposed to XOMAT film (Eastman Kodak) overnight. Oli-
gonucleotides corresponding to base pairs 1392 to 1412 5V-
CCCCCACCTCAAATTCTGGACTC-3V, 1420 to 1440 5V-
S.R. Patel, G.R. Dressler / DevelCTCTTCAAAGGAAGATAAGGCTC-3V, and 1657 to 1677
5V-CAACCCGGGCGCGCCATCTACAC-3V and compli-
mentary strands, all with 5V-GATC-3V ends were annealed
and end-labeled with Klenow and 32-P-dCTP for EMSA
analysis.
For Sp1 EMSA analysis, nuclear proteins were incubated
in 10 Al of the same buffer as described above, except with
the addition of 0.1 mM ZnSO4 and 10000 cpm of end-
labeled oligonucleotide, for 30 min at room temperature.
For competition experiments, 100-fold excess unlabelled
DNA was added to the binding reactions. For antibody
supershifting, 0.1 Ag of anti-Sp1 (sc-420X Santa Cruz)
was added after 15 min (Merchant et al., 1999). The
DNA–protein complexes were resolved on a 4% non-
denaturing polyacrylamide gel in Tris–Borate–EDTA buff-
er at 120 V for 2 h. Gels were dried and exposed to XOMAT
film (Eastman Kodak) overnight. The oligonucleotide 5V-
GGATTCGGGGCGGGGCAGGGAGATCT-3V, containing
the core Sp1 binding site, and complementary strand were
annealed and end-labeled with Klenow and 32-P-dCTP.
This oligonucleotide and Sp1 antibody were a kind gift
from J. Merchant.
Protein purification and peptide sequencing
Nuclear extract was prepared from 40 roller bottles of
HEK 293 cells as described above. The nuclear extract was
loaded onto a SP sepharose fast flow column (Amersham
Pharmacia Biotech, Piscataway, NJ) pre-equilibrated in Z
buffer (Fig. 5B). After extensive washing, proteins were
eluted with a stepwise KCl gradient in Z buffer. The
fractions containing the highest binding activity estimated
by EMSA were pooled and dialyzed against Z buffer with
0.1 M KCl. This fraction was applied to a single-stranded
DNA cellulose column (Sigma), and the flow-through and
first wash fraction were pooled and reapplied to a SP
sepharose column. The samples were fractionated and
dialyzed as described above. Two hundred fifty micrograms
of annealed, 5V biotinylated upper strand 1392 oligo was
added to the SP purified fractions and incubated at 4jC for 1
h. Six hundred microliters of immobilized Neutravidin
(Pierce, Rockford, IL) pre-equilibrated in Z buffer was
added, and the sample was rotated at 4jC for an additional
1 h. The flow-through and first wash fraction were pooled
and denoted the FINAL purification fraction.
The 2D EMSA was performed as follows: 55 Ag of final
purified extract was incubated with 11 Ag poly dIdC and 1
Ag of annealed specific oligo 1657 or the nonspecific oligo
1392 as a control. To visualize protein–DNA complex
migration, 32-P labeled 1657 probe was loaded in the outer
lanes of the gel. The DNA–protein complexes were re-
solved on a 8% polyacrylamide gel in 0.5 X TBE at 150V
for 5 h. The wet gel was exposed to XOMAT film overnight
at room temperature and the DNA–protein complex excised
and soaked in 1X SDS-PAGE Lamelli buffer for 5 min. The
gel fragment was loaded horizontally onto a 12% SDS-
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at 250V for 2.5 h. The gel was stained using the Silverquest
staining kit (In Vitrogen). A single unique band in the
extract with the specific oligo was excised and sequenced
by the Harvard Microchemistry Facility, Cambridge, MA,
using microcapillary reverse-phase HPLC nano-electrospray
tandem mass spectrometry (ALC/MS/MS) on a Finnigan
LCQ DECA quadrupole ion trap mass spectrometer.
Western blotting
Approximately 1–10 Ag of total protein was boiled in
1  SDS-PAGE loading buffer and run on 12% PAGE.
After transfer to PVDF membranes, membranes were
blocked with 5% milk in TBS and incubated overnight with
1 Ag of antibodies against Yin Yang 1 per milliliter in 1 
TBS–1% milk–0.1% Tween 20 (TBSTM). Membranes
were washed three times for 15 min (each time) in TBSTM
and incubated with horseradish peroxidase-conjugated anti-
mouse antibodies (Amersham). Membranes were washed
three times in TBSTM and two times in TBS for 15 min
(each time) and visualized by chemiluminescence (NEN).
To assess the integrity of the embryonic kidney and liver
proteins, 25 Ag of each extract was boiled in 1  SDS-
PAGE loading buffer and run on 8% PAGE. The presence ofFig. 1. (A) Schematic representation of the 5VPax2 locus and the vectors used f
approximately 25 and 15 kb of sequence upstream and downstream of the transcri
indicated. (B) DNAse hypersensitive site mapping of the 9-kb HindIII and 4.6-k
either kidney or liver were digested with increasing amounts of DNAseI and the D
indicated. The hypersensitive sites (1 and 2) are indicated and map to the same pSp1 (sc-59 Santa Cruz) and proliferating cell nuclear anti-
gen, PCNA (610664, BD Biosciences, Franklin Lakes, NJ)
were assessed according to the manufacturers directions.
Cell culture and transient transfection
HEK 293 cells (ATCC) were cultured in Dulbecco’s
modified Eagle’s medium (glucose concentration, 450 mg/
dl) supplemented with heat-inactivated 10% fetal bovine
serum and 100 U/ml penicillin and 100 mg/ml streptomycin
under humidified 5% CO2/95% air at 37jC. HepG2 human
hepatoma cells (ATCC) were grown in Eagles minimal
essential medium supplemented with nonessential amino
acids and heat-inactivated 10% fetal bovine serum and
100 U/ml penicillin and 100 mg/ml streptomycin under
humidified 5% CO2/95% air at 37jC. Subconfluent cells
in six-well plates were transfected using 1–1.6 Ag of total
plasmid DNA and 3 Al of Fugene 6 as described by the
manufacturer (Roche Molecular Biochemicals). One micro-
gram of luciferase reporter plasmid was co-transfected with
various doses of effector plasmid pCMV YY1 and 0.05 Ag
of pCMV-h-gal, a h-galactosidase reporter plasmid used to
monitor transfection efficiency. Forty hours after transfec-
tion, cells were harvested and extracts were prepared using
the Promega cell lysis reagent according to the manufactur-or this study. The cosmid cos26 contains the first two exons (boxes) with
ption start site. The position of the DNAse hypersensitive sites (1 and 2) are
b BamHI fragments using the probes as indicated. Embryonic nuclei from
NA analyzed by Southern blotting after digestion with HindIII or BamHI as
ositions (arrows) using the different enzymes.
Fig. 2. Expression of the 4.1lacZ transgene in embryos at various times gestation. The Pax2 genotype is indicated. (A) E8.0 embryo with 4 somites shows
expression at the midbrain–hindbrain (MH) boundary and very few lacZ positives cells starting to appear in the prospective intermediate mesoderm (IM,
arrow). (B) E8.5 embryo with 8 somites now shows strong lacZ expression in the intermediate mesoderm starting at about somite 4 and extending caudally. (C)
By E10.5 expression is limited to the nephric duct (ND) in both wild-type and Pax2 mutants (D). (E) Expression persists in the nephric duct and the ureteric
bud (UB) in E11.5 in wild types. (F) Pax2 mutants show some degeneration of the nephric duct and lack a ureteric bud. LacZ expression begins to appear
patchy. (G) In E12.5 wild-type embryos, lacZ expression is still evident in the duct and strong in the branching ureteric bud epithelia of the kidney (K) derived
from the duct. (H) E12.5 Pax2 mutants have little lacZ activity at this stage because much of the nephric duct has degenerated. (I) Isolated metanephroi and
ureteric buds from transient transgenic embryos at E12 carrying either the 4.1lacZ gene. (J) Isolated metanephroi from E12 transgenics carrying the 4.1DlacZ
reporter constructs. Note the reduction in lacZ activity due to the deletion encompassing DNAse hypersensitive site I.
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lysate after the addition of firefly luciferase substrate
(Promega) using a TD-20/20 luminometer (Turner Designs).
h-Galactosidase was assayed as previously described (Bro-
phy et al., 2001). Each experiment was repeated four times
and the results presented as average F standard error of the
mean. The data are normalized for h-galactosidase activity
and expressed as relative light units (RLU). Statistical
significance was analyzed by with the Student’s t test for
two independent variables.Results
In order to identify promoter and enhancer elements
directing Pax2 expression within the early intermediate
mesoderm and in the developing urogenital system, the lacZ
gene was fused to potential Pax2 promoter elements (Fig.
1A) and analyzed in transgenic mice for expression. Con-
sistent with previously published reports (Kuschert et al.,Fig. 3. Characterizing the DNAseI hypersensitive site. (A) DNAseI footprint analy
buffer alone () or with increasing amounts of kidney nuclear extracts before diges
with respect to the upstream BamHI site (n1). Note the hypersensitive region aroun
bottom strand. (B) EMSA analysis using oligonucleotides corresponding to pote
extracts or buffer alone () were used to look for factors binding to the region id
EMSA analysis with probe 1657–77 using kidney nuclear extract (NE) or buffe
competition with increasing amounts of unlabeled 1657–1677 oligo, from 5- to 1
and Sp1. (D) A homology matrix of human versus mouse upstream Pax2 sequence
conservation flanking this region. (E) The nucleotide sequence from mouse (M
mismatch. The position of the conserved YY1 binding site is underlined.2001; Pfeffer et al., 2002), an approximately 4.1-kb fragment
upstream of the Pax2 coding region was able to confer
expression within the intermediate mesoderm beginning at
around embryonic day 8.5 (E8.5) (Fig. 2). Expression was
found in the midbrain–hindbrain region beginning at E8.0
(Fig. 2A) and in the intermediate mesoderm at E8.5 (Fig.
2B). As development proceeds to E 9.5, Pax2 expression
continues in the midbrain–hindbrain region and nephric duct
in both the wild-type and Pax2 homozygous null embryos
(not shown). Nephric duct expression persists in both wild-
type and Pax2 mutants at E10.5, but starts to become patchy
in the posterior duct of Pax2 mutants (Figs. 2C, D). By E
11.5, the ureteric duct has branched from the nephric duct
and invaded the metanephric mesenchyme, and branched
once in the wild-type embryos (Fig 2E). LacZ expression is
still evident in the nephric duct of the Pax2/ embryo (Fig.
2F), but in contrast to the wild-type embryo, no ureteric bud
is seen. By E12.5, the ureteric bud has branched several
times in the wild-type embryos, and lacZ expression persists
in the derivatives of the nephric duct, but not the metanephricses of the region surrounding site 1. End labeled DNAwas incubated with
tion with limited amounts of DNAseI. The nucleotide positions are indicated
d n1662–1671. Several other weakly protected regions are indicated on the
ntial protein/DNA interacting domains. Kidney (K) and liver (L) nuclear
entified in (A). Note kidney-specific proteins binding to n1662–1671. (C)
r alone (left lane). The specificity of the nuclear factor is demonstrated by
00-fold excess, and with 100-fold excess of nonspecific oligos: 1392, 1420,
s. The arrow points to the region around n1657–1677. Also, note the lack of
o) and human (Hu) corresponding to n1647–1679 contains only a single
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minimal lacZ staining in what is left of the nephric duct (Fig.
2H). There was neither qualitative nor quantitative difference
between the cos26/lacZ transgene that contained 25-kb
upstream and 15-kb downstream of exon 1, the 9.0lacZ
transgene and the 4.3lacZ transgene (data not shown). All
transgenes recapitulated the early intermediate mesodermal
pattern, the nephric duct and ureteric bud branches, but failed
to express lacZ in the metanephric mesenchyme and its
derivatives. Furthermore, the data show that Pax2 is not
required to regulate this promoter.
DNAseI hypersensitive site mapping was used to iden-
tify potential regions of protein DNA interactions in the
4.1-kb fragment (Fig. 1B). Using E16–E17 kidney and
livers nuclei, two kidney-specific DNAseI hypersensitive
sites were mapped within the 4.1-kb BamHI fragment and
a larger 9.0 HindIII fragment (Fig. 1B). Site 1 was found
approximately 1600 nucleotides downstream of the BamHI
site (nuc. 1) and a second site 2 mapped very near the start
of transcription. The intensity of the sites in the kidney
nuclei were quite low, as only a small percentage of cells
at this stage actually express the Pax2 gene, yet the same
sites were found with two different probes and enzymatic
digests.
To clarify the role of DNAseI hypersensitive site 1, a
334-base pair deletion flanking this site was created
(4.1DlacZ) and the expression evaluated in E11.5–12
transient transgenic embryos (Figs. 2I, J). Using the wild-
type 4.1lacZ transgene, 11 embryos were positive for the
transgene by PCR analysis and 8 embryos stained for h-
galactosidase. Strong staining is seen in the midbrain–
hindbrain region (data not shown) and in the nephric duct
and its derivatives (Fig. 2I). Using the 4.1DlacZ transgene,
seven embryos were PCR positive and five stained for h-
galactosidase in the hindbrain, but expression levels were
significantly reduced in the urogenital region (Fig. 2J).
Thus, deletion of these 334 base pairs of DNA markedly
attenuated h-galactosidase expression in the developing
nephric duct and its derivatives, but did not affect the
hindbrain.
These data suggested that an important regulatory ele-
ment was near DNAse hypersensitivity site 1 that was
essential for high level expression in the intermediate
mesoderm. Additional strategies were devised to delineate
the DNA sequences and binding proteins that positivelyFig. 4. Purification of the DNAseI hypersensitive site binding factor. (A)
EMSA using embryonic kidney, HEK 293, NIH 3T3, and embryonic liver
nuclear extracts shows similar protein DNA complexes in kidney and 293
cells with the DNA probes spanning n1657–1677. (B) Purification scheme
starting with 293 cell nuclear extracts. Fractionated extracts are cleared of
single-stranded DNA binding proteins and nonspecific DNA binding
proteins before a preparative 2D EMSA. (C) Silver stain of samples eluted
from the preparative EMSA using a specific probe (1657–1677) and a
nonspecific control probe. Note the single major band unique to the specific
probe at around 65 kD (arrow).
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kidney and liver nuclear extracts on the 334-base pair
fragment showed a strong hypersensitive site between base
pairs 1662 and 1671 (Fig. 3A). EMSA analysis revealed that
at least one protein in the E17 kidney nuclear extract, but
not the liver extract, bound to the oligo containing this
DNAseI hypersensitive site (n1657–1677, Fig. 3B). Spec-
ificity was confirmed by competition with increasing
amounts of unlabelled probe or nonspecific competitors
(Fig. 3C). Several weaker footprints were also mapped,
but these neither showed kidney-specific binding proteins
by EMSA (Fig. 3B) nor competed for binding (Fig. 3C).
The potential for n1657–1677 to contain important regula-
tory elements is underscored by its conservation between
human and mouse Pax2 promoter sequences (Fig. 3D).
Between the mouse sequence from 1646 to 1679 and the
corresponding human promoter region, 32 out of 33 nucleo-
tides are identical (Fig. 3E). There is no other significant
homology between mouse and human within 500 bp flank-
ing either side of this sequence.
Several cell lines were screened for proteins that bound
to n1646–1679 containing the DNAseI hypersensitive site.
Human embryonic kidney 293 cells had a high concentra-
tion of a protein(s) that migrated with the same mobility in
EMSAs as the E17 kidney nuclear extract (Fig. 4A).Fig. 5. Confirmation that the kidney-specific Factor is YY1. (A) Western blot of n
nuclear extract; L, liver nuclear extract; 293, HEK 293 cell nuclear extract; SP, poo
Samples contain equivalent amounts of DNA binding activity, not total protein lo
probe 1657–1677 and supershifted with a-YY1 or a-Ku86 (control) antibodies as
a-YY1 shifts the entire complex towards the top of the gel, whereas a-Ku86 has n
1), purified recombinant YY1 (lane 2), 293 cell nuclear extract (lane 3), and em
complex migrates at the same position as the major complex observed in 293 ce
extracts shows equivalent Sp1 and Sp3 DNA binding activity. Nuclear extracts us
used to show specificity as indicated. Also, a-Sp1 is able to supershift the upper S
Western blots showing the integrity of the nuclear extracts from kidney (K) and liv
either PCNA or Sp1.Nuclear extracts from 293 cells were fractionated using SP
sepharose fast flow, single-stranded DNA cellulose, and
DNA affinity chromatography (Fig. 4B). For final purifica-
tion, a modified 2D EMSA approach was employed. After
EMSA on a non-denaturing gel, the fragment of gel that
contained the protein–DNA complex was excised and run
on denaturing SDS-PAGE. A nonspecific oligo probe con-
trolled for co-migrating proteins. When the profile of
proteins in the lane with the specific oligonucleotide is
compared to the control oligonucleotide, one unique band
was apparent (Fig. 4C). This band was excised and se-
quenced by mass spectroscopy. The protein was identified
as Yin Yang 1 (YY1). To confirm that YY1 was indeed the
protein that bound the region around 1657–77 of the Pax2
promoter, we used several methods. Western blotting con-
firmed the presence of YY1 in the E 17 kidney extract and
in the various fractions from the purification process, but not
in the E 17 liver nuclear extract (Fig. 5A). Moreover, a YY1
antibody supershifted the DNA–protein complexes using
the probe spanning DNAse hypersensitive site 1, whereas a
nonspecific antibody had no effect on the protein–DNA
complex (Fig 5B). Inspection of the sequence between 1657
and 77 revealed a conserved YY1 consensus binding site
from base pairs 1667 to 1676 of the mouse Pax2 promoter
(underlined in Fig 3E). Furthermore, we used purifieduclear extracts and fractionated samples using a-YY1 antibodies. K, kidney
led elutions from second SP sepharose column; final, DNA-affinity purified.
aded. (B) Same protein lysates as in (A) but used in EMSA analysis with
indicated. Only the shifted species, not the free probes, are shown. Note that
o effect. (C) EMSA analysis with probe 1657–77 using control buffer (lane
bryonic kidney nuclear extract (lane 4). Note that the purified YY1/DNA
lls and kidney. (D) EMSA analysis with kidney (K) and liver (L) nuclear
ed are as indicated. A 100-fold excess of Sp1 oligo competitor (comp.) was
p1-specific protein/DNA complexes observed in both kidney and liver. (E)
er (L). Note that no observable differences are seen with antibodies against
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5C). The YY1/DNA complex migrated to the same position
as the major complexes observed in both kidney and 293
cell nuclear extracts, suggesting that these were the same
proteins. Surprisingly, we did not see YY1 protein or
activity in the embryonic liver extracts. To show that the
liver nuclear extracts were still intact, we did EMSA
analysis with an oligo that contains a core Sp binding motif
and is known to bind both Sp1 and Sp3 (Merchant et al.,
1999) (Fig. 5D). In addition, Western blots for both Sp1 and
PCNA (Fig. 5E) indicate that the liver nuclear extracts were
not degraded.
To determine if the YY1 site was necessary to promote
high level expression in the nephric duct, additional con-
structs were tested using enhanced green fluorescent protein
as a reporter (Fig. 6). As expected, the 4.1EGFP transgene
produced high level expression in a nephric duct and
ureteric bud-specific pattern (Fig. 6B), but a specific 11-
bp deletion of the YY1 binding element significantly
attenuated GFP expression in the kidney (Fig. 6C). We then
utilized the 0.4-kb NarI–ApaI fragment fused to a 1.3-kb
KpnI–NotI fragment (pApa0.4, Fig. 6A) as a minimal Pax2
promoter/enhancer for expression in the nephric duct and
hindbrain, as described (Kuschert et al., 2001). Expression
from this minimal Pax2 promoter, which like 4.1DEGFP
also lacks the YY1 site, produced a very weak EGFP signalFig. 6. Analysis of minimal Pax2 enhancer with the YY1 site. (A) Schematic of
length promoter with deletion of the YY1 element (4.1DYY1), the minimal
(pYY1Apa0.4) or downstream (pApa0.4 YY1) of the enhancer. The number of ex
construct are represented by + signs. EGFP expression was visualized by a Leica
5000 video camera. The film speed was set at 800, and exposure time was 4 s for
construct. Abbreviations used on the promoter in (A): H, HindIII; N, NotI, B, Bain a nephric duct and ureteric bud (Fig. 6D). Thus, we
inserted the YY1 element either upstream or downstream of
the 0.4-kb NarI–ApaI Pax2 promoter fragment. Insertion of
a single YY1 site upstream of the minimal Pax2 promoter
did not affect expression levels to a significant degree (Fig.
6E). However, when a single YY1 site was inserted between
the minimal Pax2 promoter and the reporter gene, expres-
sion levels were enhanced to near wild-type levels (Fig. 6F).
Thus, the position of the conserved YY1 binding site
relative to the minimal enhancer is important for establish-
ing correct expression levels.
Finally, to assess the ability of YY1 to enhance tran-
scription from the Pax2 promoter, we transfected HEK293
and HepG2 cells with a reporter plasmid that contained the
4.1 BamHI/NotI fragment fused to the luciferase gene (Fig.
7). From a basal activity of approximately 300 RLU, the
full-length 4.1 promoter fragment was activated more than
10-fold with 500 ng of co-transfected YY1 in the transient
assays. Using the deletion construct pD4.1GL3 as a reporter,
the base line activity was reduced by more than 50% in both
cell types. Since YY1 expression is readily detected in both
293 and HepG2, the reduction of basal activity may be a
direct effect of the YY1 site deletion. Upon co-transfection
of increasing amounts of YY1, the pD4.1GL3 plasmid also
showed increasing amounts of luciferase activity, though the
relative activity of pD4.1GL3 was consistently less than theEGFP reporter constructs outlining the full-length (4.1) promoter, the full-
kidney-specific enhancer (pApa 0.4), with YY1 sites inserted upstream
pressing transgenics is indicated and the relative expression levels of each
MZIII FL fluorescence microscope and photographed with a SONY DKC
all embryos. (B–F) Representative fluorescent images are shown for each
mHI; Na, NarI; A, ApaI; K, KpnI.
Fig. 7. Transient transfection assays. HEK293 or HepG2 cells were
transfected with the luciferase reporter plasmids p4.1GL3 or pD4.1GL3 and
increasing amounts of CMV-YY1 as indicated. Transfection efficiencies
were normalized to an internal standard and relative light units (RLU) are
plotted. Each data point is the average of four experiments with the error
bars showing one standard error from the mean.
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promoter region used in vivo is responsive to YY1.Discussion
Pax2 and the closely related gene Pax8 are two of the
earliest known transcription factors whose expression are
restricted to the intermediate mesoderm (Bouchard et al.,
2000; Dressler et al., 1990). The activity of either Pax2 or
Pax8 is necessary for the early intermediate mesoderm to
form the nephric duct, a single epithelial tube extending
caudally from the 12th somite (Bouchard et al., 2002). The4.1-kb Pax2 promoter-lacZ transgene recapitulates the early
intermediate mesoderm and hindbrain specific expression of
Pax2, even in Pax2 null embryos. These data suggest that
Pax2 does not positively feedback to regulate its own
promoter. Similarly, lacZ expression is observed in Pax8
or Pax2 knock-ins, at these early stages, even in the
combined absence of any Pax2 or Pax8 protein (Bouchard
et al., 2002). Moreover, our data suggest that all of the
information required for high level expression of Pax2 in the
nephric duct and its derivatives is present on this 4.1-kb
promoter, as there was no qualitative or quantitative differ-
ence in h-galactosidase staining between this smaller pro-
moter and the expression of the larger cos26 construct,
which contained 25 kb of upstream sequence and 15 kb of
downstream sequence. However, no expression of Pax2 was
noted with either construct in the metanephric mesenchyme
suggesting that other enhancer elements further upstream or
downstream regulate the expression of Pax2 in this tissue.
The expression pattern obtained with the complete
4.1lacZ reporter was similar to that described in previous
studies (Kuschert et al., 2001; Pfeffer et al., 2002). These
reports also described a minimal Pax2 enhancer, whose
expression levels were significantly reduced with weak
and patchy h-gal staining in the nephric duct. This minimal
kidney-specific enhancer did not contain the conserved,
upstream DNAseI hypersensitive site with YY1 binding
activity. In fact, the activity of the minimal kidney enhancer
was similar to our 4.1D construct driving either lacZ or
EGFP. When we replaced the YY1 site downstream of the
minimal kidney enhancer, expression levels returned to
those observed with the full-length 4.1 fragment. The data
indicate a critical role for the YY1 site in maintaining high
levels of expression in the intermediate mesoderm and
nephric duct. While the minimal Pax2 enhancer provides
tissue-specific control in transgenic mice, deletion of this
enhancer in a Pax2 BAC transgene had little measurable
effect in mice (Pfeffer et al., 2002). These studies suggest
some redundant elements control early expression in the
intermediate mesoderm and hindbrain, though they did not
specifically address the DNAseI hypersensitive site 1 and
YY1.
In order to identify proteins binding hypersensitive site
1, we developed a novel approach in the final purification
stages. With preparative EMSA gels, we isolated the
protein DNA fractions from the neutral acrylamide gel
and subsequently denatured this protein–DNA complex
on SDS/PAGE as a second dimension. The unique protein,
observed with the specific probe and not the control probe,
was identified as the transcription factor YY1. That our
DNA binding protein was indeed YY1 was confirmed by
using antibodies to inhibit or supershift the DNA/protein
complexes observed from either whole or fractionated
kidney nuclear extracts. Furthermore, the migration of
complex containing purified, recombinant YY1 was similar
to that observed in our extracts. While YY1 is often called
ubiquitous, we did not see protein or activity in the
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promoter is highly conserved between human and mouse,
with only one base mismatch in a stretch of 33, further
supporting a critical role in the regulation of the Pax2 locus.
This is the only conserved sequence between human and
mouse within an approximately 1-kb region. The next
major area of conservation lies upstream in the minimal
kidney and hindbrain-specific enhancer regions. In both
mouse and humans, Pax2 function is dependent on gene
dosage and, by inference, protein levels. Thus, elements
such as the YY1 site that are essential for high level
expression must be conserved in vertebrates for proper
meso- and metanephric kidney development.
The YY1 gene encodes a 414 amino acid Kruppel-
related zinc-finger containing transcription factor that binds
to CGCCATNTT consensus DNA elements (Shi et al.,
1997; Thomas and Seto, 1999). YY1 can activate or
repress expression of many cellular and viral genes
depending on its relative concentration (Bushmeyer et al.,
1995), other cell-type specific tissue factors (Shi et al.,
1997) and the promoter sequences surrounding the YY1
binding sites (Shrivastava and Calame, 1994). YY1 is able
to recruit proteins of the basal transcription machinery
including TFIIB (Usheva and Shenk, 1994) and TATA
binding protein (Austen et al., 1997). YY1 is also able to
recruit histone deacetylases, 1, 2, and 3 (Yang et al., 1996,
1997), and the co-activator proteins with acetylase activity
CREB-binding protein (CBP) (Austen et al., 1997; Lee et
al., 1995) and p300. More recently, YY1 has been shown
to bind to and recruit the histone H4 (Arg 3)-specific
methyltransferase, PRMT1, to a YY1 activated promoter,
thus linking this protein to the nuclear matrix (Rezai-Zadeh
et al., 2003).
An essential role for YY1 in murine development was
described by Donohoe et al. (1999), as loss-of-function
mutants exhibit embryonic lethality shortly after implanta-
tion. Expression was widespread with high levels of YY1
mRNA in the somites, limb bud, and tail bud. YY1 was
detected in E17 kidney nuclear extracts, but not liver
extracts, suggesting some level of tissue-specific control.
Consistent with the its role in development, Tan et al. (2002)
described the presence of three YY1 sites on the Msx2
promoter that enhanced expression. Other homeodomain
proteins regulated by YY1 include Hoxb4 (Gilthorpe et
al., 2002) and Hoxb7 (Meccia et al., 2003). In contrast to
activation of the Hoxb7 promoter, YY1 probably serves as a
repressor of the Hoxb4 promoter. Transient activation assays
confirm that the Pax2 promoter is responsive to YY1.
Deletion of DNAse hypersensitive site 1 reduces the basal
activity of the promoter in transfected cells, though it
remains responsive to added YY1. Clearly, the YY1 binding
site at DNAse hypersensitive site 1 is more important for in
vivo expression of an integrated DNAwith native chromatin
conformation. Saturating amounts of exogenous YY1 in cell
culture may provide alternate binding sites that act to
increase activity in transfection assays.In summary, our data strongly implicate YY1 as a
transcriptional enhancer of Pax2 expression in the interme-
diate mesoderm and the nephric duct. The mechanism of
activation is still unknown, though the ability of YY1 to
recruit proteins with histone acetyl transferase activity to the
active site of transcription of Pax2 may be essential for
activation. In addition, how the extracellular signals respon-
sible for the Pax2 expression in the intermediate mesoderm
transduce their activities through YY1 and the kidney
enhancer remains to be elucidated.Acknowledgments
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